WTF with Prescient Therapeutics: The drug development pathway
To walk us through the process, Tylah Tully is joined by Prescient Therapeutics (ASX:PTX) CEO,...
To walk us through the process, Tylah Tully is joined by Prescient Therapeutics (ASX:PTX) CEO,...
Small Caps speaks with Prescient Therapeutics (ASX: PTX) for a general company update focused on...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO, James McDonnell, held an investor briefing...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO, James McDonnell, held an investor briefing...
Prescient Therapeutics: Explainer with CEO James McDonnell CEO James McDonnell, recorded a short video explaining...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics CEO James McDonnell talked with Proactive about the company’s clinical and regulatory progress...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.